Search Within

Saad Zafar Usmani

  1. "Population Sciences Research Program"
Formats
  1. Meeting Abstract (46)
  2. Journal Article (10)
  3. Research Letter (3)
  4. Correspondence (1)
Groups
  1. Population Sciences Research Program (60)
  2. Department of Medicine (59)
  3. Epidemiology and Biostatistics (59)
  4. Biostatistics Service (58)
  5. Hematologic Malignancies, Division of (58)
  6. Center for Hematologic Malignancies (56)

More Groups

People
  1. Andriy Derkach (57)
  2. Urvi Shah (53)
  3. Alexander Lesokhin (52)
  4. Malin Hultcrantz (50)
  5. Sham Mailankody (49)
  6. Carlyn Rose Tan (48)

More People

Years
  1. 2025 (2)
  2. 2024 (18)
  3. 2023 (22)
  4. 2022 (18)
Publications
  1. Blood (19)
  2. Clinical Lymphoma, Myeloma and Leukemia (19)
  3. Journal of Clinical Oncology (9)
  4. Blood Cancer Journal (4)
  5. Blood Advances (2)
  6. American Journal of Hematology (1)

More Publications

Publishers
  1. American Society of Hematology (21)
  2. Elsevier Inc. (20)
  3. American Society of Clinical Oncology (9)
  4. Nature Publishing Group (5)
  5. American Association for Cancer Research (1)
  6. Ferrata Storti Foundation (1)

More Publishers

Results (60)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • CD4+ T-cell lymphoma harboring a chimeric antigen receptor integration in TP53
    Journal Article

    Perica, K.; Jain, N.; Scordo, M.; Patel, R.; Eren, O. C.; Patel, U.; Gundem, G.; Domenico, D.; Mitra, S.; Socci, N. D.; more...
    New England Journal of Medicine (2025)

    Fulltext@MSK | Save
  • Evaluating serum free light chain ratio as a biomarker in multiple myeloma
    Journal Article

    Akhlaghi, T.; Maclachlan, K.; Korde, N.; Mailankody, S.; Lesokhin, A. M.; Hassoun, H.; Lu, S. X.; Patel, D.; Shah, U. A.; Tan, C. R.; more...
    Haematologica (2025)

    Fulltext@MSK | Save
  • Comparison of acute kidney injury in patients with relapsed or refractory multiple myeloma following CAR T-cell and bispecific antibody therapies
    Meeting Abstract

    Nishimura, N.; Mailankody, S.; Nemirovsky, D.; Derkach, A.; Costa, B. A.; Farzana, T.; Shaikh, A.; Latcha, S.; Gutgarts, V.; Jurgens, E. M.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Body mass index trajectory during triplet induction therapy: Clinical implications in newly diagnosed multiple myeloma
    Meeting Abstract

    Thirugnanasambandam, R. P.; Firestone, R. S.; Derkach, A.; Furberg, H.; Shekarkhand, T.; Rueda, C.; Maclachlan, K. H.; Hultcrantz, M.; Mailankody, S.; Patel, D.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Infectious complications during treatment with commercial CAR T-cell therapy and bispecific antibodies for relapsed/refractory multiple myeloma
    Meeting Abstract

    Jurgens, E. M.; Shekarkhand, T.; Farzana, T.; Rueda, C.; Nemirovsky, D.; Derkach, A.; Firestone, R. S.; Nishimura, N.; Miller, K.; Costa, B. A.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Feasibility and implementation of the ASH Research Collaborative's COVID-19 OutcomeS in Myeloma and the Impact of VaCcines (COSMIC): A decentralized, real-world evidence study for patients with multiple myeloma to monitor outcomes related to COVID-19 vaccines and infections
    Meeting Abstract

    Wood, W. A.; Semmel, E. A.; James, S.; Neuberg, D. S.; Hewitt, K.; Anderson, K. C.; Kumar, S.; Schroeder, M. A.; Chung, D. J.; Rosenberg, A. S.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Clinical outcomes of teclistamab among MajesTEC-1 eligible and ineligible population in the real-world setting for the treatment of relapsed/refractory multiple myeloma
    Meeting Abstract

    Tan, C.; Derkach, A.; Maclachlan, K.; Hultcrantz, M.; Hassoun, H.; Mailankody, S.; Shah, U.; Rajeeve, S.; Hashmi, H.; Shah, G.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2024)

    Fulltext@MSK | Save
  • Impact of granulocyte colony-stimulating factor exposure on cytokine release syndrome during bispecific antibody initiation in relapsed/refractory multiple myeloma
    Meeting Abstract

    Wang, A.; Shekarkhand, T.; Derkach, A.; Nemirovsky, D.; Tan, C.; Hamadeh, I.; Firestone, R.; Jurgens, E.; Miller, K.; Korde, N.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2024)

    Fulltext@MSK | Save
  • Incidence and clinical impact of acute kidney injury: A comparison of CAR T-cell and bispecific antibody therapies
    Meeting Abstract

    Nishimura, N.; Mailankody, S.; Nemirovsky, D.; Derkach, A.; Costa, B.; Farzana, T.; Jurgens, E.; Firestone, R.; Nath, K.; Chung, D.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2024)

    Fulltext@MSK | Save
  • CMV reactivation during treatment with bispecific antibodies for relapsed/refractory multiple myeloma
    Meeting Abstract

    Jurgens, E.; Shekarkhand, T.; Rueda, C.; Nemirovsky, D.; Derkach, A.; Firestone, R.; Miller, K.; Costa, B.; Rajeeve, S.; Lesokhin, A.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2024)

    Fulltext@MSK | Save